



Office of the Secretary

UNITED STATES OF AMERICA  
FEDERAL TRADE COMMISSION  
WASHINGTON, D.C. 20580

January 30, 2012

Susan Chandler  
State of Florida

Re: *In the Matter of Laboratory Corporation of America Holdings  
and Orchid Cellmark Inc., File No. 111-0155*

Thank you for your comments regarding the proposed consent order accepted by the Federal Trade Commission for public comment in the above-captioned matter. Your message describes numerous objections to making the consent order final. The Commission has reviewed your comments in connection with its decision concerning whether to accord final approval to the proposed consent order.

The Commission has placed your comment on the public record pursuant to Rule 4.9(b)(6)(ii) of the Commission's Rules of Practice, 16 C.F.R. § 4.9(b)(6)(ii), and it has been given careful consideration. The investigation examined all of the markets in which the transaction was likely to have a competitive impact, including the forensic testing services market. Because that market is relatively unconcentrated, the parties taken together do not account for a large portion of that market, and there were no other indications of likely anticompetitive effects in that market, no action was taken regarding the forensic testing services component of the acquisition. The Commission has determined that the public interest would best be served by issuing the Decision and Order in final form without modification. A copy of the final Decision and Order is enclosed for your information. Relevant materials also are available from the Commission's website at <http://www.ftc.gov>.

It helps the Commission's analysis to hear from a variety of sources in its work on antitrust and consumer protection issues, and we appreciate your interest in this matter.

By direction of the Commission.

Donald S. Clark  
Secretary